MedTrace Logo

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

NCT02260154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2019-06-06

Study results available
· View outcomes & findings →

Summary

Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms

Conditions

  • Post-cholecystectomy Gastrointestinal Spasms

Interventions

DRUG

Mebeverine

Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed

Sponsors & Collaborators

Principal Investigators

  • Tatiana Vladimirova, MD, PhD · Abbott

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02260154 on ClinicalTrials.gov